Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Legend-Janssen CAR-T Therapy Approved in US for Multiple Myeloma

publication date: Mar 1, 2022

Nanjing Legend and Janssen Pharma reported the US FDA approved their partnered CAR-T therapy as a fifth-line therapy for relapsed or refractory multiple myeloma. Carvykti™ (ciltacabtagene autoleucel) will compete against an already approved CAR-T, Abecma, which was developed by Bristol Myers Squibb and bluebird. According to Endpoints News, the Legend-Janssen CAR-T is priced at $465,000, slightly higher than the $419,500 for the BMS drug. Janssen-Legend contend that their drug has an advantage in long-term efficacy that will overcome their drug's higher price and second-to-market status. More details....

Stock Symbol: (NSDQ: LEGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.